Egetis Therapeutics AB (publ) (STO:EGTX)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.580
-0.010 (-0.22%)
Mar 2, 2026, 5:21 PM CET
Market Cap1.81B -15.8%
Revenue (ttm)62.40M +35.4%
Net Income-342.50M
EPS-0.93
Shares Out395.16M
PE Ration/a
Forward PE7.52
Dividendn/a
Ex-Dividend Daten/a
Volume488,440
Average Volume664,219
Open4.550
Previous Close4.590
Day's Range4.420 - 4.660
52-Week Range3.025 - 7.070
Beta1.13
RSI41.27
Earnings DateFeb 26, 2026

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 40
Stock Exchange Nasdaq Stockholm
Ticker Symbol EGTX
Full Company Profile

Financial Performance

In 2025, Egetis Therapeutics AB's revenue was 62.40 million, an increase of 35.36% compared to the previous year's 46.10 million. Losses were -342.50 million, -0.32% less than in 2024.

Financial Statements